Size | Price | Stock | Qty |
---|---|---|---|
10mg |
|
||
50mg |
|
||
100mg |
|
||
250mg |
|
||
500mg |
|
||
1g |
|
||
Other Sizes |
|
Purity: ≥98%
Risperidone (R-64766; R64766 and Risperdal), an marketed atypical antipsychotic, is a potent multi-targeted antagonist for dopamine, serotonin, adrenergic and histamine receptors, it has been approved for use in the treatment of schizophrenia and bipolar disorder. In particular, striatal and limbic structure neurons exhibit DA and serotonin (5HT) receptor binding when taking risperidone. Endogenous growth factor turnover may be influenced by risperidone, as evidenced by its substantial effects on brain nerve growth factor (NGF) levels.
Targets |
5-HT2A ( Ki = 0.17 nM ); α2c-adrenergic receptor ( Ki = 1.3 nM ); α2c-adrenergic receptor ( Ki = 1.3 nM ); D2 receptor ( Ki = 3.57 nM ); D3 receptor ( Ki = 3.6 nM ); D2L Receptor ( Ki = 4.16 nM )
|
||
---|---|---|---|
ln Vitro |
|
||
ln Vivo |
|
||
Animal Protocol |
|
||
References |
Molecular Formula |
C23H27FN4O2
|
|
---|---|---|
Molecular Weight |
410.48
|
|
Exact Mass |
410.21
|
|
Elemental Analysis |
C, 67.30; H, 6.63; F, 4.63; N, 13.65; O, 7.80
|
|
CAS # |
106266-06-2
|
|
Related CAS # |
Risperidone-d4; 1020719-76-9; Risperidone hydrochloride; 666179-74-4; Risperidone mesylate; 666179-96-0
|
|
Appearance |
Solid powder
|
|
SMILES |
CC1=C(C(=O)N2CCCCC2=N1)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F
|
|
InChi Key |
RAPZEAPATHNIPO-UHFFFAOYSA-N
|
|
InChi Code |
InChI=1S/C23H27FN4O2/c1-15-18(23(29)28-10-3-2-4-21(28)25-15)9-13-27-11-7-16(8-12-27)22-19-6-5-17(24)14-20(19)30-26-22/h5-6,14,16H,2-4,7-13H2,1H
|
|
Chemical Name |
3-[2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl]-2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one
|
|
Synonyms |
|
|
HS Tariff Code |
2934.99.9001
|
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
|
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
|
|||
---|---|---|---|---|
Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 1 mg/mL (2.44 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 10.0 mg/mL clear DMSO stock solution to 400 μL of PEG300 and mix evenly; then add 50 μL of Tween-80 to the above solution and mix evenly; then add 450 μL of normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 1 mg/mL (2.44 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 10.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 1 mg/mL (2.44 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 2.4362 mL | 12.1809 mL | 24.3617 mL | |
5 mM | 0.4872 mL | 2.4362 mL | 4.8723 mL | |
10 mM | 0.2436 mL | 1.2181 mL | 2.4362 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
NCT04940039 | Active Recruiting |
Drug: Risperidone 3 mg Drug: Paliperidone Palmitate 50 mg eq. |
Schizophrenia | Janssen-Cilag International NV | July 22, 2021 | Phase 4 |
NCT03522168 | Active Recruiting |
Drug: Risperidone Drug: Aripiprazole |
Weight, Body | Duke University | January 10, 2019 | N/A |
NCT05480046 | Recruiting | Drug: Risperidone ISM | Schizophrenia | Rovi Pharmaceuticals Laboratories | October 18, 2022 | N/A |
NCT05779241 | Recruiting | Drug: LYN-005 Drug: Risperidone |
Schizophrenia Schizoaffective Disorder |
Lyndra Inc. | April 2023 | Phase 3 |
NCT05890768 | Recruiting | Drug: Lumateperone Drug: Risperidone |
Psychosis | University of New Mexico | May 11, 2023 | Phase 4 |